Bicycle Therapeutics (NASDAQ:BCYC) Stock Rating Upgraded by Wall Street Zen

Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other brokerages have also commented on BCYC. Morgan Stanley reaffirmed a “sell” rating and issued a $13.00 target price on shares of Bicycle Therapeutics in a research report on Tuesday, March 17th. Royal Bank Of Canada cut their price target on Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday, March 18th. Citizens Jmp decreased their price objective on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating for the company in a report on Wednesday, March 18th. Needham & Company LLC lowered their target price on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Finally, Truist Financial set a $8.00 target price on Bicycle Therapeutics in a report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $14.50.

Bicycle Therapeutics Trading Down 4.4%

NASDAQ:BCYC opened at $4.35 on Friday. Bicycle Therapeutics has a 12 month low of $4.30 and a 12 month high of $9.69. The stock has a market capitalization of $301.76 million, a price-to-earnings ratio of -1.38 and a beta of 1.65. The firm has a fifty day simple moving average of $5.78 and a two-hundred day simple moving average of $6.75.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.71. The firm had revenue of $47.96 million for the quarter, compared to analyst estimates of $7.08 million. Bicycle Therapeutics had a negative net margin of 301.66% and a negative return on equity of 33.21%. Equities analysts predict that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

Insider Activity

In other Bicycle Therapeutics news, CEO Kevin Lee sold 10,989 shares of Bicycle Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $6.46, for a total transaction of $70,988.94. Following the completion of the transaction, the chief executive officer owned 618,996 shares in the company, valued at approximately $3,998,714.16. The trade was a 1.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Alethia Young sold 4,334 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $6.49, for a total value of $28,127.66. Following the sale, the chief financial officer directly owned 87,081 shares of the company’s stock, valued at $565,155.69. This represents a 4.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 38,029 shares of company stock worth $251,966. 8.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Principal Financial Group Inc. boosted its holdings in Bicycle Therapeutics by 64.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock worth $8,889,000 after acquiring an additional 451,135 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Bicycle Therapeutics in the second quarter valued at about $320,000. Jefferies Financial Group Inc. lifted its position in shares of Bicycle Therapeutics by 12.8% during the second quarter. Jefferies Financial Group Inc. now owns 461,100 shares of the company’s stock valued at $3,205,000 after purchasing an additional 52,211 shares in the last quarter. Long Focus Capital Management LLC lifted its position in shares of Bicycle Therapeutics by 7.7% during the third quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock valued at $10,981,000 after purchasing an additional 101,402 shares in the last quarter. Finally, Armistice Capital LLC boosted its holdings in Bicycle Therapeutics by 4.8% during the second quarter. Armistice Capital LLC now owns 2,800,000 shares of the company’s stock worth $19,460,000 after purchasing an additional 128,000 shares during the last quarter. 86.15% of the stock is owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.